István has several years of working experience in scientific research in chemical engineering in Europe (TUB, BP) and in the US (NJIT). From 2000, he was working for ComGenex, Inc. (acquired by AMRI Hungary in 2006). He was responsible for business development of State-of-the-Art technology innovations, at the early years. Later, he was in charge of multiple duties as follows: a) as Grant Coordinator, he supervised application procedures of grant proposals and coordinated national and international interdisciplinary R&D projects; b) as Intellectual Property Manager, he organized all patent and trademark issues of the company, and c) as legal consultant he dealt with the company’s legal instruments and issues: read and wrote international agreements and contracts, and advised related challenges. Between 2000 and 2008, István raised 32+ million euros for research, coordinated and prepared 29 patent and 14 trademark applications and supervised their filing and maintenance procedures. Today, István works at TargetEx Ltd. a biotech small enterprise. He is the co-founder and managing director of the innovation management startup, InnoEx Ltd.
Before appointed to COO of ThalesNano Inc. in 2004, he was a Member of the Board at ComGenex Inc. between 2000 and 2006. Earlier he worked at CompuDrug International as the Director of Marketing, before that he was involved in commercial real-estate with an international real-estate investment company. He was heading the Hungarian American Chamber of Commerce in Budapest for two years until 2000 . Founder and Vice President of the Hungarian Spin-Off & Start-Up Association, holder of the R&D 100's Award and the Hungarian Venture Capital Associaton's SME of the Year Award.
Akos is the co-founder and CEO of the high tech startup Icegel Ltd, which has received an audience award at the Intel-Berkeley International Innovation Business Plan Contest in 2006. Besides the work with his firm, Akos is working on a PhD-thesis at the ELTE University in Budapest, where he is the head of the fuel cell research laboratory. Previously, 2005-2006, Akos held the position as R&D manager at the Budapest Stock Exchange (BSE) listed company Freesoft Plc. In 2001 he founded the mobile-communication firm MoolTech, which in 2005 was acquired by a Hungarian information technology firm listed on the BSE. 1999-2001 he worked for the Bay Zoltán Research Association.
Peter Ferdinandy received an MD diploma in 1991 and a PhD degree in 1995. He became a registered clinical pharmacologist in 1999, and obtained DSc degree of the Hungarian Academy of Sciences in 2004.He completed MBA studies in Finance and Quality Management in 2004 at the Budapest University of Technology and Economics. He worked for 2 years at the Department of Pharmacology, University of Alberta, Edmonton, Canada, as a postdoctoral fellow of MRC Canada. He was the head of the Cardiovascular Projects at Biorex Co, (partner of Abbott) a US-Hungarian biotech company, and consulted preclinical and clinical pharmacological projects for several pharmaceutical companies all over the world in the last 15 years. Currently he is a professor of biochemistry and clinical pharmacology, head of the Cardiovascular Research Group, Department of Biochemistry, University of Szeged (for further details, see www.cardiovasc.com). He published over 80 papers in international peer-reviewed journals with close to 400 impact factors and over 1100 independent citations. He is member of the editorial boards of Br J Pharmacol, J Mol Cell Cardiol, and J Pharmacol Toxicol Methods, and the member of the European Committee of the International Society for Heart Research.
You can contact me via email at .